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Abstract: BACKGROUND Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with
ventricular arrhythmias (VA) and sudden cardiac death (SCD). A model was recently developed to predict
incident sustained VA in patients with ARVC. However, since this outcome may overestimate the risk
for SCD, we aimed to specifically predict life-threatening VA (LTVA) as a closer surrogate for SCD.
METHODS We assembled a retrospective cohort of definite ARVC cases from 15 centers in North America
and Europe. Association of 8 prespecified clinical predictors with LTVA (SCD, aborted SCD, sustained, or
implantable cardioverter-defibrillator treated ventricular tachycardia >250 beats per minute) in follow-
up was assessed by Cox regression with backward selection. Candidate variables included age, sex,
prior sustained VA (฀30s, hemodynamically unstable, or implantable cardioverter-defibrillator treated
ventricular tachycardia; or aborted SCD), syncope, 24-hour premature ventricular complexes count, the
number of anterior and inferior leads with T-wave inversion, left and right ventricular ejection fraction.
The resulting model was internally validated using bootstrapping. RESULTS A total of 864 patients with
definite ARVC (40±16 years; 53% male) were included. Over 5.75 years (interquartile range, 2.77-10.58)
of follow-up, 93 (10.8%) patients experienced LTVA including 15 with SCD/aborted SCD (1.7%). Of the
8 prespecified clinical predictors, only 4 (younger age, male sex, premature ventricular complex count,
and number of leads with T-wave inversion) were associated with LTVA. Notably, prior sustained VA did
not predict subsequent LTVA (P=0.850). A model including only these 4 predictors had an optimism-
corrected C-index of 0.74 (95% CI, 0.69-0.80) and calibration slope of 0.95 (95% CI, 0.94-0.98) indicating
minimal over-optimism. CONCLUSIONS LTVA events in patients with ARVC can be predicted by a
novel simple prediction model using only 4 clinical predictors. Prior sustained VA and the extent of
functional heart disease are not associated with subsequent LTVA events.
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ORIGINAL ARTICLE
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A Multinational Collaboration
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Antoine Andorin , MD; Crystal Tichnell, MGC, RN; Brittney Murray , MS; Katja Zeppenfeld , MD, PhD;  
Maarten P. van den Berg , MD, PhD; Folkert W. Asselbergs , MD, PhD; Arthur A.M. Wilde , MD, PhD; Andrew D. Krahn , MD; 
Mario Talajic , MD; Lena Rivard, MD; Stephen Chelko , PhD; Stefan L. Zimmerman , MD; Ihab R. Kamel, MD, PhD;  
Jane E. Crosson, MD; Daniel P. Judge , MD; Sing-Chien Yap , MD, PhD; Jeroen F. Van der Heijden, MD, PhD;  
Harikrishna Tandri , MD; Jan D.H. Jongbloed, PhD; J. Peter van Tintelen , MD, PhD; Pyotr G. Platonov , MD, PhD;  
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BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with ventricular arrhythmias (VA) and 
sudden cardiac death (SCD). A model was recently developed to predict incident sustained VA in patients with ARVC. 
However, since this outcome may overestimate the risk for SCD, we aimed to specifically predict life-threatening VA (LTVA) 
as a closer surrogate for SCD.
METHODS: We assembled a retrospective cohort of definite ARVC cases from 15 centers in North America and Europe. 
Association of 8 prespecified clinical predictors with LTVA (SCD, aborted SCD, sustained, or implantable cardioverter-
defibrillator treated ventricular tachycardia >250 beats per minute) in follow-up was assessed by Cox regression with 
backward selection. Candidate variables included age, sex, prior sustained VA (≥30s, hemodynamically unstable, or implantable 
cardioverter-defibrillator treated ventricular tachycardia; or aborted SCD), syncope, 24-hour premature ventricular complexes 
count, the number of anterior and inferior leads with T-wave inversion, left and right ventricular ejection fraction. The resulting 
model was internally validated using bootstrapping.
RESULTS: A total of 864 patients with definite ARVC (40±16 years; 53% male) were included. Over 5.75 years (interquartile 
range, 2.77–10.58) of follow-up, 93 (10.8%) patients experienced LTVA including 15 with SCD/aborted SCD (1.7%). Of the 
8 prespecified clinical predictors, only 4 (younger age, male sex, premature ventricular complex count, and number of leads 
with T-wave inversion) were associated with LTVA. Notably, prior sustained VA did not predict subsequent LTVA (P=0.850). 
A model including only these 4 predictors had an optimism-corrected C-index of 0.74 (95% CI, 0.69–0.80) and calibration 
slope of 0.95 (95% CI, 0.94–0.98) indicating minimal over-optimism.
CONCLUSIONS: LTVA events in patients with ARVC can be predicted by a novel simple prediction model using only 4 clinical 
predictors. Prior sustained VA and the extent of functional heart disease are not associated with subsequent LTVA events.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: arrhythmogenic right ventricular dysplasia ◼ calibration ◼ sudden cardiac death ◼ syncope ◼ ventricular tachycardia
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A
rrhythmogenic right ventricular cardiomyopathy 
(ARVC) is associated with frequent ventricular 
arrhythmias (VA) and an increased risk of sudden 
cardiac death (SCD) particularly in young and athletic 
patients.1 In the past 2 decades, significant efforts have 
been made to define the predictors of sustained VA in 
this high-risk population. Building on this work, our group 
recently published a model for individualized prediction 
of any incident sustained VA in patients with definite 
ARVC without sustained VA at baseline.2
While most clinicians agree that the risk for sustained 
VA events is, by itself, sufficient to merit consideration of 
an implantable cardioverter-defibrillator (ICD) in a patient 
with structural heart disease, it is an imperfect surrogate 
outcome for SCD as it likely overestimates SCD risk.3 For 
patients with ARVC, it is furthermore uncertain if stable VA 
and potentially fatal VA/SCD share the same predictors. 
Evidence from both clinical and translational research sug-
gests a continuum between structural and electrical disease 
phases in ARVC, which could potentially imply different 
arrhythmia mechanisms.4,5 From a clinical perspective, it is, 
therefore, possible that rapid VA/SCD is not accurately pre-
dicted by a model that predicts the risk of any sustained VA.
To address this important clinical question, we sought 
to study the determinants of potentially fatal VA and SCD 
and to develop a specific prediction model for these events 
in an adequately powered population that represents the 
largest cohort of patients with definite ARVC to date.
We believe that this approach could provide valuable 




The design of this international observational cohort study 
is similar to what has previously been described.2 In brief, 
our cohort combines longitudinal observational data from 
5 registries encompassing 6 countries (Table I in the Data 
Supplement). This study is in accordance with the current inter-
national guidelines for prognostic research,6 conforms to the 
declaration of Helsinki and was approved by local ethics and 
institutional review boards.
Study Population
From our international cohort of patients with ARVC,2 we included 
all who were diagnosed with definite ARVC by the 2010 Task 
Force Criteria.7 The present study thus excludes patients with 
arrhythmogenic cardiomyopathy not fulfilling definite diagnos-
tic criteria for ARVC. Alternate diagnoses sharing similar clinical 
characteristics were excluded as clinically indicated. We included 
patients with and without a history of sustained VA at diagno-
sis. This differs from the cohort used for the development of the 
model for any incident sustained VA in which patients with a prior 
history of sustained VA were excluded.2 To maintain patient con-
fidentiality, data and study materials will not be made available to 
other researchers for purposes of replicating the results. A limited 
data set may be made available on request.
Study Outcomes
With the aim of predicting potentially fatal VA and SCD, the pri-
mary study outcome was the time to first life-threatening VA 
(LTVA) during follow-up, defined by a composite of SCD, aborted 
SCD, ventricular fibrillation, and rapid ventricular tachycardia (VT; 
>250 beats per minute) that was either sustained (lasting ≥30 
seconds) or terminated by ICD. The choice of 250 beats per 
minute as a cutoff for rapid VT was prespecified based on the 
widespread use of this threshold for ventricular fibrillation therapy 
in many ICD studies since the PAINFREE trial (The Pacing Fast 
VT Reduces Shock Therapies Trial) in 20018,9 and in clinical prac-
tice. This cutoff for life-threatening events is also consistent with 
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LTVA life-threatening ventricular arrhythmia
PKP2 plakophilin 2
PVC premature ventricular complexes
RVEF right ventricular ejection fraction





• Improving the specific prediction of sudden cardiac 
death in arrhythmogenic right ventricular cardiomy-
opathy can help in patient selection for implantable 
cardioverter-defibrillators implantation.
• Life-threatening ventricular arrhythmia (LTVA; sud-
den cardiac death, aborted sudden cardiac death, 
ventricular tachycardia >250 beats per minute/ven-
tricular fibrillation) might have different mechanisms 
and thus different predictors versus stable ventricu-
lar arrhythmia in arrhythmogenic right ventricular 
cardiomyopathy.
WHAT THE STUDY ADDS?
• LTVA events can be predicted by a new prediction 
model that can be easily applied to clinical practice.
• As opposed to stable arrhythmia, LTVA events are 
not predicted by prior sustained arrhythmic events 
and the extent of functional alteration of either 
ventricle.
• The 4 predictors of LTVA events are younger age, 
male sex, burden of ventricular ectopy, and the 
extent of repolarization abnormalities.
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prior ARVC arrhythmic risk prediction literature.10–12 In addition, 
we recorded outcomes of any sustained VA, heart transplantation, 
cardiovascular-, and all-cause mortality.
Predictors
Based on clinical experience and the current literature, particu-
larly a recent published meta-analysis13 and a prognostic model 
for predicting incident sustained VA in patients with ARVC,2 8 
potential predictors were preselected and recorded at the time 
of diagnosis.2,11–15 These were sex, age at diagnosis, recent 
(<6 months) cardiac syncope, number of premature ventricu-
lar complexes (PVCs) on 24-hour Holter monitoring, prior sus-
tained VA events, number of anterior and inferior leads with 
T-wave inversion (TWI), and left and right ventricular ejection 
fraction (RVEF). The definitions for these predictor variables 
are presented in Table II in the Data Supplement. In addition, 
the relationship between the type of prior sustained VA event 
(only stable VT, as opposed to LTVA or unstable VT/ventricu-
lar fibrillation) was studied (definitions in Table II in the Data 
Supplement). Each predictor variable was determined at the 
time of definite diagnosis, defined as one year before to one 
year after the date of diagnosis per Task Force Criteria, but 
always before occurrence of the primary outcome.
Data Collection
Data were collected according to previously published stan-
dard operating procedures.2 All ECG tracings were reviewed 
by a core laboratory consisting of 2 cardiac electrophysiolo-
gists (Drs Cadrin-Tourigny and Tadros) blinded to the outcome 
data. Adjudication of reported genetic variants was performed 
by consensus of a team of specialists in cardiac genetics (B. 
Murray, Dr Jongbloed, Dr van Tintelen, Dr James) according 
to the American College of Medical Genetics and Genomics 
guidelines as previously described.2,16
Statistical Analysis
Analyses were performed using R version 3.5.1 (R Foundation, 
Vienna, Austria). Categorical variables are presented as fre-
quencies (percentages) and were compared using Fisher exact 
tests. Continuous variables were presented as mean±SD or 
median (interquartile range) and compared using independent 
sample t tests or Mann-Whitney U tests, as appropriate. The 
follow-up duration was calculated as the time interval from 
diagnosis to the outcome of interest or censoring. Censoring 
occurred at the most recent available clinical assessment, 
death from any other cause or heart transplantation. Event-free 
survival probabilities were estimated using the Kaplan-Meier 
method and Cox Proportional Hazard regression analysis.
Missing Data
Missing data patterns were evaluated, and the potential for bias 
was assessed by comparing the characteristics of patients with 
and without missing variables. Missingness was assumed to be 
at random and imputed using multiple imputations with chained 
equations or manually using qualitative assessment when avail-
able.17 A total of 25 imputed data sets were generated in 20 
iterations, and the final results of all analyses were combined 
using Rubin’s rules.18
Model Development
The association between potential predictors and the primary 
outcome was estimated using Cox regression. The final predic-
tors were selected via stepwise backward selection on Akaike’s 
Information Criterion.6 The discriminative performance of the 
model was calculated by Harrell’s C statistic. The model was 
converted as a function of the individual risk prediction of hav-
ing had LTVA within time t:
P LTVA t S t, ( )( ) = −1 0
exp(LP)
In which S t0 ( )  represents the estimated baseline survival 
probability at time t, and the linear predictor (LP) is the sum 
of the predictor variables in the model multiplied by their esti-
mated coefficient.
Model Validation and Calibration
Validation of the model was performed by bootstrapping 
using 200 samples. Potential optimism was estimated by the 
pooled calibration slope of the bootstrap samples.19 In addition, 
observed versus predicted values were graphically evaluated.20
Sensitivity Analyses
We assessed whether the predictions of LTVA were consistent 
in patients with and without a prior history of LTVA or unstable 
VT (according to the Table II in the Data Supplement definition) 
by performing a sensitivity analysis excluding patients who had 
already suffered these events.
Additionally, we performed another sensitivity analysis com-
paring the performance of our model in individuals with and 
without PKP2 (likely) pathogenic variants.
RESULTS
A cohort of 864 patients with definite ARVC was assem-
bled from 15 centers in 6 countries in North America and 
Europe, including the 528 patients from the previously 
published cohort.2 The average age at diagnosis was 
39.5±15.5 years and 53.4% (n=461) were male. More 
than half were probands (57.8%, n=499). Two-thirds 
(65.0%, n=539) had a (likely) pathogenic variant identified, 
predominantly a single heterozygous variant in plakophilin 
2 (PKP2; 77.6%, n=418/539). Overall, 38.8% (n=335) 
of patients had a history of sustained VA at the time of 
diagnosis including 129 (14.9%, average age 39.7±15.5 
years, 64% male, 57% with a [likely] pathogenic variant) 
with a prior history of LTVA or unstable VT. Other clini-
cal characteristics are summarized in Table 1. The study 
population was evenly distributed between North America 
(433) and Europe (431; Table III in the Data Supplement).
Overall, only 6.6% of data for the 8 prespecified predic-
tors were missing, 58.3% (n=504) of patients had com-
plete data for these predictors, and none had >50% of them 
missing. The most common missing predictor was prema-
ture ventricular complexe count on 24-hour Holter monitor.
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Outcomes
Over a median follow-up of 5.75 years (interquartile 
range, 2.77–10.58), 93 (10.8%) patients experienced 
a LTVA event, representing an event rate of 1.56%/y 
(95% CI, 1.26–1.91). This included 15 patients (1.7%) 
with SCD or aborted SCD. Overall, 375 (43.4%) patients 
experienced any sustained VA event during follow-up. 
Over the course of follow-up, 42 (4.9%) patients died 
and 35 (4.1%) had cardiac transplantation. The median 
cycle length of LTVA classified VT events was 224 ms 
(210–230) while non-LTVA VT events had a median 
cycle length of 310 ms (280–350).
As depicted on Figure 1A, history of a sustained VA 
before diagnosis was not associated with survival free from 
LTVA during follow-up (P=0.43). In contrast, prior sustained 
VA predicted recurrence of sustained VA (P<0.0001; Fig-
ure 1B). However, no significant difference was found 
regarding the severity of the prior VA event, that is, unstable 
or life-threatening, including aborted SCD, versus stable, 
on the risk of sustained VA recurrence (P=0.15).




Patients with LTVA 
in follow-up P value
Total 864 771 93  
Demographics
 Male sex 461 (53.4) 398 (51.6) 63 (67.7) 0.005
 Age at diagnosis, y 39.5±15.5 40.6±15.5 30.9±13.2 <0.001
 White ethnicity (n=809) 784 (96.9) 701 (96.8) 83 (97.6) 0.354
 Proband status 499 (57.8) 420 (54.5) 79 (84.9) <0.001
 Presence of pathogenic mutation (n=829) 539 (65.0) 474 (64.2) 65 (71.4) 0.214
 Pathogenic variant (n=809) 0.022
 PKP2 418 (50.4) 362 (49.1) 56 (61.5)  
 DSP 28 (3.4) 24 (3.3) 4 (4.4)  
 DSG2 28 (3.4) 27 (3.7) 1 (1.1)  
 DSC2 5 (0.6) 4 (0.5) 1 (1.1)  
 PLN 41 (4.9) 39 (5.3) 2 (2.2)  
 Multiple mutations 11 (1.3) 11 (1.5) 0 (0.0)  
 Other 8 (0.9) 7 (0.9) 1 (1.1)  
History
 Prior sustained VA 335 (38.8) 295 (38.3) 40 (43) 0.438
 Prior LTVA and unstable VA 129 (14.9) 111 (14.4) 18 (19.4) 0.266
 Symptoms (n=863) 626 (72.5) 545 (70.8) 81 (87.1) 0.001
 Recent cardiac syncope (n=847) 130 (15.3) 108 (14.3) 22 (23.7) 0.028
ECG/continuous ECG monitoring
 TWI in ≥3 precordial leads (n=837) 497 (59.4) 432 (57.8) 65 (73.0) 0.008
 TWI in ≥2 inferior leads (n=817) 154 (18.8) 130 (17.8) 24 (27.3) 0.046
 NSVT (n=700) 566 (70.2) 495 (68.6) 71 (84.5) 0.004
 24 h PVC count (n=553) 1069 (315–3955) 1007 (273–3637) 2860 (782–5406) 0.003
Imaging
 RVEF, %, (n=800) 42.5±10.4 42.7± 10.4 40.6±10.0 0.086
 LVEF, %, (n=824) 57.5±8.3 57.5±8.3 57.0±8.4 0.574
Treatment at baseline
 ICD 450 (52.1) 391 (50.7) 59 (63.4) 0.027
 Beta blockers (n=817) 394 (48.2) 352 (48.2) 42 (48.3) 1
 Antiarrhythmic drugs (n=816) 252 (27.0) 225 (27.3) 27 (24.1) 0.522
 VT ablation 152 (17.6) 142 (18.4) 10 (10.8) 0.091
Variables are expressed as frequency (%), mean±SD, or median (IQR). Total number of patients for a given variable mentioned if missing 
data. DSC2 indicates desmocollin-2; DSG2, desmoglein-2; DSP, desmoplakin; ICD, implantable cardioverter-defibrillator; IQR, interquartile 
range; LTVA, life-threatening ventricular arrhythmia; LVEF, left ventricular ejection fraction; NSVT, nonsustained ventricular tachycardia; PKP2, 
plakophilin-2; PLN, phospholamban; PVC, premature ventricular complex; RVEF, right ventricular ejection fraction; TWI, T-wave inversion; VA, 
ventricular arrhythmia; and VT, ventricular tachycardia.
Cadrin-Tourigny et al Sudden Death Prediction in ARVC
Circ Arrhythm Electrophysiol. 2021;14:e008509. DOI: 10.1161/CIRCEP.120.008509 January 2021 34
Model Development
Baseline characteristics of patients with and without LTVA 
during follow-up are shown in Table 1. The univariable and 
multivariable predictors of LTVA are presented in Table 2. 
All predictors except prior sustained VA, left ventricu-
lar ejection fraction, and RVEF either had a significant 
(P<0.05) or borderline significant univariable linear (or 
log-linear) relationship with the outcome. Subsequently, 
all variables were fitted into a multivariable model. Only 4 
predictors were independently associated with the out-
come: male sex (P=0.0021), younger age at diagnosis 
(P<0.0001), the 24-hour PVC count (log-linear relation-
ship; P=0.010), and the total number of leads with TWI 
(P=0.024).
The following formula allows for the calculation of the 
5-year risk of LTVA:
P LTVA at 5 years 1 927exp LP( ) . ( )= − 0
Where:
LP 6899 sex 439 age 1844 ln 24 hour PVC count
11
= × × + ×
+
0 0 0 0
0
. . . ( )
.
−
53 sum of anterior and inferior leads with TWI×
Table IV in the Data Supplement provides the probability 
of survival (S
0
(t)) at 1, 2, 3, and 4 years allowing calcula-
tion of risk for shorter time durations.
An online version of this new risk prediction model 
combined with the published sustained VA risk calcula-
tion model can be found at www.ARVCrisk.com.
Model Validation
Our prediction model had an optimism-corrected C 
statistic of 0.74 (95% CI, 0.69–0.80). Internal valida-
tion with bootstrapping resulted in a calibration slope 
of 0.95 (95% CI, 0.94–0.98), indicating only a small 
degree of over-optimism. Figure 2 visually shows cali-
bration, demonstrating good concordance between 
predicted and observed events at 1 and 5 years. Cali-
bration plots showing similarly good agreement for 
predictions of shorter duration can be found in Figure I 
in the Data Supplement.
Clinical Utility
We explored and presented the implications of using 
different risk thresholds for ICD implantation using the 
prediction model. Figure 3 depicts the clinical impact of 
using different 5-year risk thresholds for ICD use with 
solid colors representing patients who would get an ICD 
and red color representing patients with LTVA events dur-
ing this period. Implanting ICDs in patients above an arbi-
trary 4% five-year risk threshold would result implanting 
ICDs in 640 patients (74.1%) leaving 2 (0.2%) patients 
with unprotected LTVA events during 5-years of follow-
up (ie, protection rate of 97.7%, 84 patients with LTVA 
protected by an ICD/a total of 86 patients with LTVA at 
5 years). In comparison, setting an arbitrary threshold of 
10% would result in implanting ICDs in 315 (36.5%) 
leaving 23 (2.7%) patients with unprotected LTVA (pro-
tection rate 73.3%, 63 patients with LTVA protected by 
an ICD/a total of 86 patients with LTVA at 5 years). To 
Figure 1. Survival free from life-threatening ventricular arrhythmia (LTVA) and any sustained ventricular arrhythmia (VA).
The cumulative event-free survival for LTVA is plotted in A. LTVA events occurred in follow-up in 52 patients with no prior sustained VA event 
at baseline, 19 with prior LTVA/unstable ventricular tachycardia (VT) a and 23 with prior stable VT. The cumulative event-free survival for any 
VA is plotted in B. Sustained VA events occurred in follow-up in 147 patients with no prior sustained VA event at baseline, 91 with prior LTVA/
unstable VT a and 137 with prior stable VT. For both parts, 95% CIs are provided (shaded area).
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further illustrate the use of the model, Table V in the Data 
Supplement depicts the characteristics of 3 patients from 
our cohort and their calculated LTVA risk alongside with a 
comparison to the published sustained VA model.2
Sensitivity Analyses
LTVA Prediction in Patients With No Prior History of 
LTVA or Unstable VT
We performed a sensitivity analysis excluding patients 
with a prior history of unstable or LTVA to ensure that 
our predictors remain consistent in predicting incident 
LTVA. Patients presenting with aborted SCD or unsta-
ble and rapid VT would likely undergo ICD placement 
such that it is imperative for the model to perform well in 
the remaining subset. Overall, 735 patients did not have 
such prior events and had similar characteristics as the 
complete cohort (Table VI in the Data Supplement). Over 
a median follow-up of 5.64 years (2.66–10.47) 75 of 
these patients experienced a LTVA including 12 SCD/
aborted SCDs. The same predictors as for primary analy-
sis were fitted into a multivariable model. As shown in 
Table VII in the Data Supplement, the same 4 predictors 
with similar weights remained in the model. This model 
performed well with an optimism-corrected C statistic of 
0.75 (95% CI, 0.69–0.80) and a calibration slope of 0.95 
(95% CI, 0.93–0.97).
Table 2. LTVA Risk Prediction Model
 
Univariable model Multivariable (final model)
HR (95% CI) P value HR (95% CI) P value
Male sex 1.78 (1.15–2.76) 0.009 1.99 (1.28–3.10) 0.0021
Age (per year increase) 0.96 (0.94–0.97) <0.0001 0.96 (0.94–0.97) <0.0001
Recent cardiac syncope 1.69 (1.04–2.72) 0.032   
Prior sustained VA 0.96 (0.63–1.46 0.850   
24 h PVC count (ln)* 1.21 (1.06–1.39) 0.002 1.23 (1.04–1.38) 0.010
Leads with TWI anterior+inferior 1.14 (1.04–1.25) 0.005 1.12 (1.02–1.24) 0.024
RVEF (per % decrease) 1.02 (1.00–1.04) 0.095   
LVEF (per % decrease) 1.02 (0.99–1.04) 0.320   
HR indicates hazard ratio; LTVA, life-threatening ventricular arrhythmia; LVEF, left ventricular ejection fraction; PVC, premature ventricular 
complex; RVEF, right ventricular ejection fraction; TWI, T-wave inversion; and VA, ventricular arrhythmia.
*PVC count had a log-linear relationship.






























Total (n)   = 864
LTVA (n)  = 93
Avg. group size (n)  = 173
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Figure 2. Calibration plot showing the agreement between predicted (x axis) and observed (y axis) 5-year risk of the primary 
outcome of life-threatening ventricular arrhythmia (LTVA).
Triangles represent binned Kaplan-Meier estimates with 95% CIs for quintiles of predicted risk. Straight line is the continuous calibration 
hazard regression. Dotted line represents perfect calibration. Spike histogram on the x axis reflects the number of patients with a predicted risk 
corresponding to the x axis value.
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Comparison of the Performance of the Model in 
PKP2 Variant Carriers Versus Noncarriers
We performed another sensitivity analysis to assess the 
potential differences in the performance of our model in 
patients with and without a PKP2 (likely) pathogenic vari-
ant. First, adding PKP2 variant status to our model caused 
almost no shift in the predictive effect of any of the included 
variables (Table VIII in the Data Supplement). Second, we 
evaluated separately the performance of our model in 
those with and without a PKP2 (likely) pathogenic variants. 
The calibration curves showed equally good performance 
in both groups (Figure II in the Data Supplement).
DISCUSSION
Main Findings
In this article, we used a large cohort of patients with 
multinational ARVC to specifically assess LTVA in ARVC 
as a surrogate marker that more closely approximates 
SCD. This effort had 2 aims.
First, we sought to get a better understanding of the 
specific determinants of potentially fatal arrhythmias 
in an adequately powered ARVC population, with the 
underlying rationale that these might differ from those 
for stable sustained VT.
Second, we intended to refine the prediction of these 
events by providing a distinct prediction model for LTVA 
that can be used in all newly diagnosed patients with 
ARVC in addition to the published incident sustained VA 
prediction model.2
The 3 main findings are as follows: first, prior history 
of any VA or LTVA/unstable VT did not predict subse-
quent LTVA. This finding differs from the outcome any 
sustained VA which, as expected, was predicted by prior 
sustained VA events. Second, after evaluating several 
predefined clinical and demographic predictors, only 4 
ALL >1% >2% >3% >4% >5% >6% >7% >8% >9% >10% None
No LTVA, No ICD 0 13 57 133 222 282 341 414 468 500 526 778
(0%) (1.5%) (6.6%) (15.4%) (25.7%) (32.7%) (39.4%) (48%) (54.1%) (57.8%) (60.9%) (90%)
No LTVA, ICD 778 765 721 645 556 496 437 364 310 278 252 0
(90%) (88.5%) (83.4%) (74.7%) (64.3%) (57.4%) (50.6%) (42.2%) (35.9%) (32.2%) (29.1%) (0%)
LTVA, No ICD 0 0 1 1 2 5 10 10 16 21 23 86
(0%) (0%) (0.1%) (0.1%) (0.2%) (0.6%) (1.2%) (1.2%) (1.9%) (2.4%) (2.7%) (10%)
LTVA, ICD 86 86 85 85 84 81 76 76 70 65 63 0
(10%) (10%) (9.8%) (9.8%) (9.8%) (9.3%) (8.8%) (8.8%) (8.1%) (7.5%) (7.3%) (0%)
ICD, total 864 851 806 730 640 577 513 440 380 343 315 0
(100%) (98.5%) (93.3%) (84.5%) (74.1%) (66.8%) (59.4%) (50.9%) (44%) (39.7%) (36.5%) (0%)























ICD, LTVA No ICD, LTVA ICD, no LTVA No ICD, no LTVA
Figure 3. Outcomes of patients associated with model-based implantable cardioverter-defibrillator use thresholds.
The implications of using implantable cardioverter-defibrillators (ICD) in all (left bar) or none (right bar) of the patients are shown. The bars 
show the impact of using different ICD placement thresholds based on the 5-year risk calculated by our model. Each bar represents the 
complete cohort (n=864) and color coding represents the proportion of patients experiencing life-threatening ventricular arrhythmia (LTVA; red) 
or absence thereof (blue) as well as the placement (solid colors) vs the nonplacement (striped colors) of an ICD. The number of patients in 
each of the four categories is presented in the table below.
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remained independently associated with LTVA: younger 
age, male sex, PVC count, and the number of leads with 
TWI. Notably, the severity of functional alteration (ie, 
RVEF, left ventricular ejection fraction) was not asso-
ciated with LTVA in multivariable analyses. Third, LTVA 
events can be predicted with reasonable accuracy by a 
risk prediction model that has adequate discrimination (C 
statistic of 0.74) and consistency through internal valida-
tion (calibration slope of 0.95).
LTVA as a Closer Surrogate for SCD in ARVC
With the appropriate recognition of the significant risk of 
VA in ARVC and subsequent widespread use of ICDs, 
SCD has fortunately become a rare occurrence after 
the diagnosis of ARVC is established. Conducting a 
randomized controlled trial of ICD use would no longer 
be ethical such that surrogate outcomes are required 
in studies designed to inform decision-making for ICD 
placement. The most widely used surrogate is a com-
posite of any sustained or ICD treated VA, as used in 
the recently published risk prediction model for incident 
VA.2 While the underlying risk of SCD is known to be 
overestimated when using ICD treated events as a sur-
rogate,3 the extent of this overestimation might be par-
ticularly important in ARVC as the difference between 
the rate of VA events and underlying rate of SCD is 
higher than what is found in other conditions such as in 
hypertrophic cardiomyopathy, reflecting the higher rate 
of scar-related hemodynamically stable monomorphic 
VT in ARVC.21 In the cohort used to develop the initial 
arrhythmic risk calculator for incident VA, only 36% of 
events (53/146 sustained VA events) were LTVA.2 We 
thus believe that restricting the outcome to LTVA, while 
not replacing the more comprehensive outcome of any 
sustained VA, could provide incremental information on 
the risk of SCD. More closely, targeting potentially lethal 
arrhythmias can be of particular interest in resource-lim-
ited settings where event rates must be higher to justify 
ICDs. This model may also provide new information for a 
more comprehensive approach to the shared decision-
making for ICD implantation. The LTVA model might be 
of particular importance in patients with borderline indi-
cations, in those who are reluctant to accept this therapy, 
and in cases where the risk of ICD-related complications 
is deemed higher.
Identified Predictors and Prior Studies
While any sustained VA has been the most commonly 
used outcome in ARVC risk prediction research, only 
a few studies have specifically reported on the predic-
tion of LTVA using a similar definition as in the pres-
ent study.11,12,14,15 Given the limited sample size in each 
cohort and lower frequency of LTVA events, interpre-
tation is uniformly hampered by insufficient power to 
discern the independent effect of individual predictors. 
Similarly to our study, identified predictors of LTVA have 
included younger age at presentation,12,14 male sex,15 and 
higher PVC burden.12 Our results thus further support the 
importance of male sex22 and younger age as predictors 
and highlight the importance of PVC count as an eas-
ily measured indicator of electrical activity and instability 
of the disease. On the contrary, prior sustained VA was 
interestingly not predictive of LTVA events in the pres-
ent study. This may be surprising at first glance. Yet, the 
predictive value of prior sustained events for incident 
LTVA has been inconsistent in the literature. Two studies 
reported no association between prior VT11,14 and sub-
sequent unstable VA, with only 1% of patients with VT 
subsequently developing ventricular fibrillation11 in one 
study. Conversely, a recent large series reported hemo-
dynamically stable VT to be a predictor of subsequent 
lethal VA23 but the end point was substantially different 
as it excluded rapid VT and included electrical storm. LV 
dysfunction24 was associated with SCD in one study and 
syncope10 with LTVA in another. RV dysfunction has not 
been associated specifically with LTVA in prior litera-
ture nor in this study despite being a good predictor of 
any sustained VA outcomes,2,13 illustrating that unstable 
arrhythmias might occur before scar burden negatively 
affects RVEF.
The Specific Determinants of LTVA and 
Mechanistic Rationale
Interestingly, we found that the predictors of LTVA differ 
from those associated with any sustained VA by not being 
predicted by the extent of functional impairment (RVEF, 
left ventricular ejection fraction), nor by prior sustained 
VA or syncopal events. These findings are consistent 
with the long recognized notion that an early electrical 
phase of the disease predisposes to rapid unstable VA 
and is independent from the severity of the underly-
ing substrate. This concept is now further supported by 
accumulating clinical4 and experimental evidence.5,25–27 
More data now link desmosomes to other components 
of the intercalated disk including the sodium channel 
and gap junction.25–27 More recently, conduction delays 
and electrogram fractionation developing before detect-
able cardiac imaging and histological abnormalities have 
also been reported in human and murine desmoplakin 
mutation carriers.5 Furthermore, inflammatory infiltration 
has long been recognized as a histopathologic feature of 
ARVC,28 and patients with ARVC have elevated levels of 
circulating inflammatory cytokines.29,30 More recent work 
in a murine model and in induced pluripotent stem cells 
demonstrated that myocytes produce and secrete potent 
inflammatory cytokines.31 Thus, inflammatory signaling in 
ARVC may act as both intrinsic and extrinsic contributors 
in aberrant electrophysiology and histopathologic remod-
eling early in disease pathogenesis. While the clinical 
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correlations of these phases and mechanisms of disease 
with arrhythmic outcomes have yet to be elucidated, they 
could explain why identified predictors do not depend on 
the burden of scar as a substrate for re-entry and do 
not include prior sustained or nonsustained VA. Rather, 
this form of disease instability could perhaps be better 
explained by interactions between desmosomes and 
other electrical cellular components as well as inflam-
matory signals.
Clinical Utility of a Prediction Model for LTVA
This second prediction model for arrhythmic risk in ARVC 
is by no means intended to replace the published model 
for predicting incident sustained VA in newly diagnosed 
patients with ARVC.2 Rather, the intent is to expand the 
probabilistic framework for decision making for physicians 
and patients. Each model provides different information. 
Whereas the model with incident sustained VA is highly 
sensitive in capturing SCD, it is likely to overestimate the 
true risk of SCD. On the contrary, restricting the outcome 
to LTVA enhances specificity for SCD but could potentially 
lead to the exclusion of slower events that may degener-
ate into more rapid potentially fatal VA if left untreated. We 
thus propose that the clinical shared decision-making pro-
cess should take into account the 2 predictions obtained 
for a patient with no prior history of VAs when considering 
the important decision of ICD use for primary prevention. 
For example, in a patient wanting to minimize risk of SCD, 
the decision process might rely more on the predictions of 
the sustained VA model than on the more stringent pre-
dictions of the LTVA model. This process in illustrated in 
Table V in the Data Supplement. Finally, these 2 predictive 
models, as any other prediction tool in medicine, are not 
intended to substitute for clinical judgement but rather to 
augment it by providing pertinent individualized informa-
tion to facilitate the shared decision-making process.
Another concern stemming from the fact that these 
2 outcomes, LTVA and any sustained VA, have a differ-
ent set of predictors is that the sustained VA prediction 
model might disproportionally under-estimate the risk of 
LTVA in a certain profile of patients. Reassuringly how-
ever, patients with the lowest calculated risk of sustained 
VA as per the published sustained VA risk model, also 
experience a low LTVA event rate while patients who 
experienced a LTVA event were at significantly higher 
calculated risk of any sustained VA than patients who 
did not suffer these events (Figure III in the Data Supple-
ment). Finally and importantly, despite not being inde-
pendent predictors of LTVA, prior sustained events are 
powerful predictors of recurrent sustained VA events 
with >50% of patients suffering recurrences at 5 years 
(Figure 1B). We thus do not suggest that our findings 
should impact the usually recommended approach of 
ICD implantation in secondary prevention for patients 
with structural heart disease.
Limitations
Our cohort is drawn from North-European and North 
American academic centers with a population predomi-
nantly of white descent with a high rate of pathogenic 
PKP2 variants. Caution should thus be exerted when 
extrapolating our results to different populations. While 
the model performed equally well in patients with and 
without pathogenic PKP2 variants, external validation 
of our model will be an important additional step in 
the future. In particular, the model may underperform 
in cohorts with genotypes poorly represented in this 
study for instance Naxos disease patients or patients 
with a TMEM43 founder variant. Importantly, we only 
included patients with a definite diagnosis of ARVC 
thus excluding patients in the concealed phase of the 
disease, patients with a possible or borderline ARVC 
diagnosis or with non-ARVC forms of arrhythmogenic 
cardiomyopathy in which our results cannot be applied. 
Although a widely used measure of RV function, RVEF 
might lack sensitivity in detecting subtle changes in 
early structural disease32,33 that could potentially be 
valuable predictors of LTVA.
Finally, while being a closer surrogate for SCD than 
all sustained VA, LTVA still represents an imperfect out-
come. Despite being a widely used threshold and typically 
indicative of a significant clinical event, the cutoff of 250 
beats per minute may nevertheless still overestimate the 
underlying risk for SCD while potentially missing slower 
events that could degenerate into lethal arrhythmias.
Conclusions
In patients with ARVC, LTVA events are not indepen-
dently predicted by prior sustained VA events, nor by the 
extent of functional heart disease. Independent predic-
tors of LTVA are young age, male sex, burden of ventricu-
lar ectopy and total number of anterior and inferior leads 
with TWI. These life-threatening events can be accurately 
predicted by a novel prediction model that can be used 
in any newly diagnosed patient with definite ARVC. An 
integrative approach using both prediction models (ie, all 
sustained VA and LTVA) has the potential to provide cli-
nicians and patients with complementary data to inform 
shared decision making for ICD implantation in ARVC.
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